Vaccinex

Vaccinex

Biotechnology, 1895 Mt Hope Avenue, Rochester, New York, 14620, United States, 51-200 Employees

vaccinex.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 58********

Who is VACCINEX

Vaccinex (NASDAQ: VCNX) is a clinical stage biotechnology company pioneering a differentiated approach to treating cancer and progressive neurodegenerative diseases through the inhibition...

Read More

map
  • 1895 Mt Hope Avenue, Rochester, New York, 14620, United States Headquarters: 1895 Mt Hope Avenue, Rochester, New York, 14620, United States
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $10 Million to $25 Million
  • Maurice Zauderer CEO:   Maurice Zauderer

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from VACCINEX

Vaccinex Org Chart and Mapping

VP-Level

Ernest Smith

Chief Scientific Officer and Senior VP Research

Employees

Scott Royer

Chief Financial Officer

Maria Scrivens

Director of Technology Development

Christine Reilly

Research and Development Scientist

Shuying Shi

Senior Research Scientist, Project Leader

Loretta Mueller

Director, Laboratory Operations

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Vaccinex

Answer: Vaccinex's headquarters are located at 1895 Mt Hope Avenue, Rochester, New York, 14620, United States

Answer: Vaccinex's phone number is 58********

Answer: Vaccinex's official website is https://vaccinex.com

Answer: Vaccinex's revenue is $10 Million to $25 Million

Answer: Vaccinex's SIC: 2834

Answer: Vaccinex has 51-200 employees

Answer: Vaccinex is in Biotechnology

Answer: Vaccinex contact info: Phone number: 58******** Website: https://vaccinex.com

Answer: Vaccinex (NASDAQ: VCNX) is a clinical stage biotechnology company pioneering a differentiated approach to treating cancer and progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The Companys lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers damaging inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimers Disease, with ongoing exploration of potential Phase 3 development in Huntingtons disease. The Company has also developed a proprietary drug discovery platform, ActivMAb, that it is leveraging thru strategic collaborations, particularly by exploiting its unique capability to select high value antibodies against important multi-pass membrane receptors.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access